Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecan
Phase 1/2Active 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Neoplasms
Conditions
Triple Negative Breast Neoplasms
Trial Timeline
Dec 21, 2018 → Feb 26, 2027
NCT ID
NCT03742102About Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecan
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecan is a phase 1/2 stage product being developed by AstraZeneca for Triple Negative Breast Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT03742102. Target conditions include Triple Negative Breast Neoplasms.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03742102 | Phase 1/2 | Active |
Competing Products
20 competing products in Triple Negative Breast Neoplasms